NCT05430360View on ClinicalTrials.gov

Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for the Treatment of Metastatic/recurrent Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

January 4, 2022

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2025

Conditions

Solid Tumor

Interventions

BIOLOGICAL

GT201

Autologous tumor infiltrating lymphocyte injection

Trial Locations (1)

Unknown

RECRUITING

The First Hospital of Zhejiang University, Hangzhou

Sponsors

Lead Sponsor

Grit Biotechnology

All Listed Sponsors

lead

Grit Biotechnology

INDUSTRY

NCT05430360 - Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for the Treatment of Metastatic/recurrent Advanced Solid Tumors | Biotech Hunter | Biotech Hunter